We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of AAV9 Gene Therapy in Participants With Canavan Disease (CANaspire)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04998396
Recruitment Status : Recruiting
First Posted : August 10, 2021
Last Update Posted : March 29, 2022
Sponsor:
Information provided by (Responsible Party):
Aspa Therapeutics

Brief Summary:
The main objective of this trial is to evaluate the safety, tolerability, and pharmacodynamic activity of BBP-812, an investigational AAV9-based gene therapy, in pediatric participants with Canavan disease.

Condition or disease Intervention/treatment Phase
Canavan Disease Biological: AAV9 BBP-812 Phase 1 Phase 2

Detailed Description:
Canavan disease is an ultra-rare, profoundly disabling and fatal disease with no approved therapy. The Sponsor is developing BBP-812, an investigational gene therapy product for systemic delivery in participants with Canavan disease. BBP-812 is a recombinant adeno-associated virus serotype 9 (rAAV9) vector engineered to deliver the aspartoacylase (ASPA) transgene under control of a ubiquitous promoter to restore ASPA expression in both neuronal and non-neuronal cell types.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 18 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/2 Open-Label Study of the Safety and Clinical Activity of Gene Therapy for Canavan Disease Through Administration of an Adeno-Associated Virus (AAV) Serotype 9-Based Recombinant Vector Encoding the Human ASPA Gene
Actual Study Start Date : September 8, 2021
Estimated Primary Completion Date : October 31, 2024
Estimated Study Completion Date : October 31, 2028


Arm Intervention/treatment
Experimental: Dose-Finding Phase: BBP-812 Dose Level 1 (Cohort 1)
Participants will receive a single intravenous (IV) infusion of low-dose BBP-812 on Day 0 in the dose-finding phase of the study.
Biological: AAV9 BBP-812
Sterile solution for injection for 1-time use via volumetric infusion pump

Experimental: Dose-Finding Phase: BBP-812 Dose Level 2 (Cohort 2)
Participants will receive a single IV infusion of high-dose BBP-812 on Day 0 in the dose-finding phase of the study.
Biological: AAV9 BBP-812
Sterile solution for injection for 1-time use via volumetric infusion pump

Experimental: Enrollment Expansion Phase: BBP-812
Participants will receive a single IV infusion of BBP-812 at a selected dose from the dose-finding phase on Day 0 in expansion phase of the study.
Biological: AAV9 BBP-812
Sterile solution for injection for 1-time use via volumetric infusion pump




Primary Outcome Measures :
  1. Number of Participants With Adverse Events (AEs) [ Time Frame: Baseline up to Week 52 ]
  2. Change From Baseline to 12 Months Post-Infusion in Urine N-acetylaspartate (NAA) Levels [ Time Frame: Baseline, Month 12 ]
  3. Change From Baseline to 12 Months Post-Infusion in Central Nervous System (CNS) NAA, as Measured by Magnetic Resonance Spectroscopy (MRS) [ Time Frame: Baseline, Month 12 ]

Secondary Outcome Measures :
  1. Change from Baseline to Week 52 in Gross Motor Assessment, Gross Motor Function Measure-88 [ Time Frame: Baseline, Week 52 ]
  2. Change from Baseline to Week 52 in Fine Motor Assessment, Bayley-4 [ Time Frame: Baseline, Week 52 ]
  3. Change from Baseline to Week 52 in Cognitive Assessment, Bayley-4 [ Time Frame: Baseline, Week 52 ]
  4. Change from Baseline to Week 52 in Communication Assessment, Bayley-4 [ Time Frame: Baseline, Week 52 ]
  5. Change from Baseline to Week 52 in Adaptive Function, Vineland-3 [ Time Frame: Baseline, Week 52 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   up to 30 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  • Maximum age for inclusion is 30 months.
  • Participant has stable health in the opinion of the investigator and as confirmed by medical history and laboratory studies with no acute or chronic hematologic, renal, liver, immunologic, or neurologic disease (other than Canavan disease).
  • Participant has biochemical, genetic, and clinical diagnosis of Canavan disease:

    • Elevated urinary NAA and
    • Biallelic mutation of the ASPA gene determined at Screening or documented in the participant's medical history.
    • Active clinical signs of Canavan disease

Key Exclusion Criteria:

  • Tests positive for total anti-AAV9 antibodies determined by enzyme-linked immunosorbent assay (ELISA).
  • Received prior gene therapy or other therapy (including vaccines) involving AAV.
  • Participant is receiving high-dose therapy with immunosuppressants.
  • Participant has significantly progressed Canavan disease characterized as:

    • Presence of continuous/constant decerebrate or decorticate posturing,
    • Recurrent status epilepticus, or
    • Recalcitrant seizures that do not respond while on 3 or more anti-epileptic medications

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04998396


Contacts
Layout table for location contacts
Contact: Canavan Disease Study Team 833-764-2267 or 617-861-4617 CANaspire@aspatx.com
Contact: David Rintell, Ed.D., VP, Head of Patient Advocacy 617-734-6778 clinicaltrials@aspatx.com

Locations
Layout table for location information
United States, Massachusetts
Massachusetts General Hospital (MGH); Center for Rare Neurological Diseases (CRND) Recruiting
Boston, Massachusetts, United States, 02114
Contact: Haley Andonian       handonian@partners.org   
Contact    617-724-1379      
Principal Investigator: Florian Eichler, MD         
Sponsors and Collaborators
Aspa Therapeutics
Additional Information:
Layout table for additonal information
Responsible Party: Aspa Therapeutics
ClinicalTrials.gov Identifier: NCT04998396    
Other Study ID Numbers: CVN-102
First Posted: August 10, 2021    Key Record Dates
Last Update Posted: March 29, 2022
Last Verified: March 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Aspa Therapeutics:
Canavan Disease
AAV
AAV9
Gene therapy
Aspartoacylase
ASPA
ASPA gene
rAAV9
ACY2
Aminoacylase 2
Spongy degeneration
N-acetyl-L-aspartic acid (NAA)
N-acetylaspartate
Rare disease
Inherited Metabolic Disorders
Leukodystrophy
Leukoencephalopathies
Autosomal Recessive Disorder
Neurodevelopmental diseases
Additional relevant MeSH terms:
Layout table for MeSH terms
Canavan Disease
Hereditary Central Nervous System Demyelinating Diseases
Brain Diseases, Metabolic, Inborn
Brain Diseases, Metabolic
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Leukoencephalopathies
Demyelinating Diseases
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Genetic Diseases, Inborn
Metabolism, Inborn Errors
Metabolic Diseases